In vitro antibacterial activity of pediatric Faropenem sodium against respiratory tract pathogens in children / 中华实用儿科临床杂志

Objective:To evaluate the antibacterial activity of pediatric Faropenem sodium against common pathogens isolated from children′s respiratory tract in vitro, and to provide reference for its clinical research and application. Methods:Retrospective analysis.The minimum inhibitory concentration (MIC) of Faropenem sodium, Merope-nem, Imipenem and other antibiotics was determined by the agar dilution method.A total of 156 strains of Streptococcus pneumoniae [including 32 strains of Penicillin-susceptible Streptococcus pneumoniae (PSSP), 28 strains of Penicillin-intermediate Streptococcus pneumoniae (PISP) and 96 strains of Penicillin-resistant Streptococcus pneumoniae (PRSP)], 98 strains of Haemophilus influenza, 173 strains of Klebsiella pneumoniae, and 55 strains of Moraxella catarrhali clinical isolates were used.MIC 50, MIC 90 and the accumulative inhibition of the bacteria were investigated. Results:The MIC of Faropenem sodium against all the Streptococcus pneumoniae strains ranged from 0.010-2.000 mg/L.There was no difference in the MIC distribution of Faropenem sodium against PSSP, PISP and PRSP, and the MIC 90 value was all 1.000 mg/L.Faropenem sodium inhibited all the Haemophilus influenza strains at concentrations ranging from 0.030-8.000 mg/L.There was no difference in the MIC distribution of Faropenem sodium against Haemophilus influenza with or without β-lactamase and Ampicillin resistance.The MIC 90 value was all 4.000 mg/L.Ho-wever, the MIC of Faropenem sodium against Klebsiella pneumoniae ranged from 0.250 to above 32.000 mg/L, and both MIC 50 and MIC 90 were greater than 32.000 mg/L.Faropenem sodium inhibited all the Moraxella catarrhalis strains at concentrations ranging from 0.030-2.000 mg/L, with MIC 50 being 0.500 mg/L and MIC 90 being 1.000 mg/L. Conclusions:Antimicrobial susceptibility testing results in vitro demonstrate that pediatric Faropenem sodium has satisfactory antibacterial activities against Streptococcus pneumoniae, Haemophilus influenza, and Moraxella catarrhalis, but comparatively weak antibacterial activities against Klebsiella pneumoniae.

Clinical distribution and epidemiological feature of nine respiratory pathogens in the northern area of Henan Province from 2014 to 2016 / 新乡医学院学报

Objective To investigate the clinical distribution and epidemiological feature of nine respiratory pathogens of acute respiratory tract infection patients in the northern area of Henan Province,in order to provide reference for clinical effective prevention and treatment of acute respiratory tract infection.Methods The clinical distribution and epidemiological feature of nine respiratory pathogens were analyzed by a retrospective review of 11 135 serum samples which were detected by indirect immunofluorescence method from December 2014 to November 2016.Results There were 2 630 cases with nine respiratory pathogens infection,the infection rate was 23.62％.The main four respiratory pathogens were mycoplasma pneumonia (16.63 ％),influenza B virus (2.41％),parainfluenza virus (2.29 ％),adenovirus (0.79％).The nine respiratory pathogens infection rate of male and female was 21.60％ (1 516/7 020) and 27.07 ％ (1 114/4 115),respectively.The nine respiratory pathogens infection rate of ＜ 1 year group,1-5 years group,6-14 years group,15-30 years group,31-50 years group and ＞ 50 years group was 8.91％ (330/3 702),31.12％ (1 424/4 576),37.36％ (634/1 697),27.10％ (90/332),24.64％ (69/280),15.13 ％ (83/548),respectively.The nine respiratory pathogens infection rate of ＜ 1 year group was lower than that of the other five groups (P ＜ 0.05).The nine respiratory pathogens infection rate of spring group,summer group,autumn group and winter group was 24.66％ (591/2 396) 、23.86％ (631/2 645) 、31.09％ (748/2 406)、17.90％ (660/3 688),respectively.The nine respiratory pathogens infection rate of autumn group was higher than that of the other three groups (P ＜ 0.05).There were 253 patients with polyinfection which all were amphimorphic polyinfection in the 2 630 patients with respiratory pathogens infection,the polyinfection rate was 2.27％.Conclusions Respiratory pathogen infection rate was different because of different gender,different age and different season.The virus was the main pathogen of acute respiratory tract infection.Because of multiplicity of infection and seasonal distribution of pathogens,the prevention of the epidemic should be strengthened in spring and autumn season especially.

In Vitro Activity of Cefditoren against Respiratory Pathogens / 감염과화학요법

BACKGROUND: Cefditoren is a third generation orally administered cephalosporin with excellent activity against respiratory pathogens. This study was performed to determine the comparative antibacterial activity of cefditoren against clinical isolates of respiratory tract infection. MATERIALS AND METHODS: According to the NCCLS guideline, in vitro activities of cefditoren and other antibiotics were tested against respiratory pathogens including 117 isolates of Streptococcus pneumoniae, 60 isolates of Haemophilus influenzae, and 31 isolates of Moraxella catarrhalis. RESULTS: The level of cefditoren activity against S. pneumoniae (MIC50/90, 0.5/1 microgram/mL) was superior to amoxicillin+/-clavulanate (MIC50/90, 4/16 microgram/mL), clarithromycin (MIC50/90, >32/>32 microgram/mL), and most of the marketed cephalosporins (MIC50/90, 8-64/16-128 microgram/mL). Although the MIC of cefditoren was relatively higher than those of new fluoroquinolone agents (MIC50/90, 0.03-1/0.06-1 microgram/mL), it was comparable to ceftriaxone (MIC50/90, 0.5/1 microgram/mL). In addition, cefditoren was active against two quinolone resistant pneumococci strains with MIC of 0.5 microgram/mL. In detail, cefditoren was active against pneumococci strains with MIC50 and MIC90 values of 0.015/0.12, 0.12/0.5, and 0.5/1 microgram/mL for penicillin-susceptible, -intermediate, and -resistant pneumococci, respectively. Cefditoren was also active against all respiratory isolates of H. influenzae (MIC50/90, 0.03/0.06 microgram/mL) and M. catarrhalis (MIC50/90, 0.03/0.05 microgram/mL) irrespective of beta-lactamase production or ampicillin resistance. CONCLUSION: Cefditoren is considered to be a good option for outpatient treatment of respiratory infections, particulary if there is concern about S. pneumoniae infection with decreased susceptibility to penicillin or beta-lactamase producing organisms.

In Vitro Activity of Cefditoren against Respiratory Pathogens / 감염과화학요법

BACKGROUND: Cefditoren is a third generation orally administered cephalosporin with excellent activity against respiratory pathogens. This study was performed to determine the comparative antibacterial activity of cefditoren against clinical isolates of respiratory tract infection. MATERIALS AND METHODS: According to the NCCLS guideline, in vitro activities of cefditoren and other antibiotics were tested against respiratory pathogens including 117 isolates of Streptococcus pneumoniae, 60 isolates of Haemophilus influenzae, and 31 isolates of Moraxella catarrhalis. RESULTS: The level of cefditoren activity against S. pneumoniae (MIC50/90, 0.5/1 microgram/mL) was superior to amoxicillin+/-clavulanate (MIC50/90, 4/16 microgram/mL), clarithromycin (MIC50/90, >32/>32 microgram/mL), and most of the marketed cephalosporins (MIC50/90, 8-64/16-128 microgram/mL). Although the MIC of cefditoren was relatively higher than those of new fluoroquinolone agents (MIC50/90, 0.03-1/0.06-1 microgram/mL), it was comparable to ceftriaxone (MIC50/90, 0.5/1 microgram/mL). In addition, cefditoren was active against two quinolone resistant pneumococci strains with MIC of 0.5 microgram/mL. In detail, cefditoren was active against pneumococci strains with MIC50 and MIC90 values of 0.015/0.12, 0.12/0.5, and 0.5/1 microgram/mL for penicillin-susceptible, -intermediate, and -resistant pneumococci, respectively. Cefditoren was also active against all respiratory isolates of H. influenzae (MIC50/90, 0.03/0.06 microgram/mL) and M. catarrhalis (MIC50/90, 0.03/0.05 microgram/mL) irrespective of beta-lactamase production or ampicillin resistance. CONCLUSION: Cefditoren is considered to be a good option for outpatient treatment of respiratory infections, particulary if there is concern about S. pneumoniae infection with decreased susceptibility to penicillin or beta-lactamase producing organisms.

In Vitro Activities of Gatifloxacin against Bacteria isolated from Respiratory Specimens of Patients of University Hospitals in Korea / 감염과화학요법

BACKGROUND: Gatifloxacin, a new 8-methoxyquinolone, has a broad-spectrum activity with expanded potency against respiratory pathogens. In this study, we examined the in vitro activity of gatifloxacin and comparators against recently isolated bacteria from respiratory specimens of patients in Korean hospitals. METHODS: Forty-nine isolates were from respiratory specimens of patients with acute exacerbations of chronic lower respiratory infections in eight university hospitals and 108 isolates were from respiratory specimens from patients of Yonsei University Hospital. Minimum inhibitory concentrations (MICs) were determined by NCCLS agar dilution method. RESULTS: MIC90 of gatifloxacin for Streptococcus pneumoniae was 1 g/mL, which was 8-fold and 2-fold lower than those of ciprofloxacin and levofloxacin, respectively. All strains of Haemophilus in fluenzae and Moraxella (Branhamella) catarrhalis were inhibited by < or =0.06 g/mL and < or =0.25 g/mL of gatifloxacin, respectively, and were susceptible to all fluoroquinolones tested. MIC90 of gatifloxacin for Klebsiella pneumoniae was 0.06 g/mL, which was 2-fold lower than those of levofloxacin and moxifloxacin. CONCLUSION: Gatifloxacin is highly active against S. pneumoniae, H. influenzae and M. (B.) catarrhalis isolated from respiratory specimens of patients of university hospitals in Korea.

In Vitro Activities of Gatifloxacin against Bacteria isolated from Respiratory Specimens of Patients of University Hospitals in Korea / 감염과화학요법

BACKGROUND: Gatifloxacin, a new 8-methoxyquinolone, has a broad-spectrum activity with expanded potency against respiratory pathogens. In this study, we examined the in vitro activity of gatifloxacin and comparators against recently isolated bacteria from respiratory specimens of patients in Korean hospitals. METHODS: Forty-nine isolates were from respiratory specimens of patients with acute exacerbations of chronic lower respiratory infections in eight university hospitals and 108 isolates were from respiratory specimens from patients of Yonsei University Hospital. Minimum inhibitory concentrations (MICs) were determined by NCCLS agar dilution method. RESULTS: MIC90 of gatifloxacin for Streptococcus pneumoniae was 1 g/mL, which was 8-fold and 2-fold lower than those of ciprofloxacin and levofloxacin, respectively. All strains of Haemophilus in fluenzae and Moraxella (Branhamella) catarrhalis were inhibited by < or =0.06 g/mL and < or =0.25 g/mL of gatifloxacin, respectively, and were susceptible to all fluoroquinolones tested. MIC90 of gatifloxacin for Klebsiella pneumoniae was 0.06 g/mL, which was 2-fold lower than those of levofloxacin and moxifloxacin. CONCLUSION: Gatifloxacin is highly active against S. pneumoniae, H. influenzae and M. (B.) catarrhalis isolated from respiratory specimens of patients of university hospitals in Korea.